(Q46366067)

English

Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT). (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

0 references

author name string

Michallet AS

1

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

Nicolini F

2

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

Fürst S

3

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

Le QH

4

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

Dubois V

5

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

Hayette S

6

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

Bourgeot JP

7

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

Tremisi JP

8

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

Thomas X

9

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

Gebuhrer L

10

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

Michallet M

11

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

language of work or name

0 references

publication date

1 March 2005

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

35

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

6

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

601-608

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1704807

0 references

Donor lymphocyte infusions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

21 January 2018

Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

21 January 2018

Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

21 January 2018

Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

21 January 2018

Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

21 January 2018

Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

21 January 2018

Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

21 January 2018

Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

21 January 2018

Molecular response to imatinib mesylate following relapse after allogeneic SCT for CML.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

21 January 2018

Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3(+) and CD4(+) lymphocytes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

21 January 2018

Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

21 January 2018

Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de Moelle (SFGM)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

7 January 2021

based on heuristic

inferred from DOI database lookup

Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

7 January 2021

based on heuristic

inferred from DOI database lookup

Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

7 January 2021

based on heuristic

inferred from DOI database lookup

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

7 January 2021

based on heuristic

inferred from DOI database lookup

Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term safety of GM-CSF (molgramostim) administration after allogeneic bone marrow transplantation for hematologic malignancies: five-year follow-up of a double-blind randomized placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1704807

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46366067&oldid=1465422434"